TCL Archive Research community needs to be prepared for budget “flattening,” NCI director says. March 25, 2005
TCL Archive Rosenberg’s Latest Results: 22% Response Seen With LAK/IL-2, 13% With High Dose IL-2 Alone April 10, 1987
TCL Archive Two Phase III Ramucirumab Trials Both Deliver Improved Overall and Progression-Free Survival October 25, 2013